## Zandelisib

Cat. No.:	HY-109198				
CAS No.:	1401436-95-0				
Molecular Formula:	$C_{31}H_{38}F_{2}N_{8}O$				
Molecular Weight:	576.68				
Target:	PI3K				
Pathway:	PI3K/Akt/mTOR				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

R

MedChemExpress

### SOLVENT & SOLUBILITY

		Mass Solvent Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.7341 mL	8.6703 mL	17.3406 mL
	5 mM	0.3468 mL	1.7341 mL	3.4681 mL	
		10 mM	0.1734 mL	0.8670 mL	1.7341 mL
	Please refer to the sol	ubility information to select the app	propriate solvent.		
Vivo		ne by one: 10% DMSO >> 90% (20 nL (4.34 mM); Suspended solution;	•		
		ne by one: 10% DMSO >> 90% cor ;/mL (4.34 mM); Clear solution	n oil		

<b>BIOLOGICAL ACTIV</b>	ТТҮ
Description	Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC <sub>50</sub> of 3.5 nM. Zandelisib functions as an antineoplastic <sup>[1][2]</sup> .
IC₅₀ & Target	ΡΙ3Κδ 3.5 nM (IC <sub>50</sub> )
In Vitro	Zandelisib inhibits PI3Ks with IC <sub>50</sub> s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM for p110α, p110β, p110γ and p110δ, respectivey <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

# Product Data Sheet

### REFERENCES

[1]. Daniel P. Gold, et al. Combination therapy. WO2019183226A1.

[2]. David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1.

### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA